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Abstract
Background: Reactive oxygen species (ROS) play an important role in aging and age-related
diseases such as Parkinson's disease and Alzheimer's disease. Much of the ROS production under
conditions of toxic stress is from mitochondria, and multiple antioxidants prevent ROS
accumulation. The aim of this study is to examine the specificity of the interaction between the
antioxidants and ROS production in stressed cells.
Methods:  Using fluorescent dyes for ROS detection and mitochondrial inhibitors of known
specificities, we studied ROS production under three conditions where ROS are produced by
mitochondria: oxidative glutamate toxicity, state IV respiration induced by oligomycin, and tumor
necrosis factor-induced cell death.
Results: We demonstrated that there are at least four mitochondrial ROS-generating sites in cells,
including the flavin mononucleotide (FMN) group of complex I and the three ubiquinone-binding
sites in complexes I, II and III. ROS production from these sites is modulated in an insult-specific
manner and the sites are differentially accessible to common antioxidants.
Conclusion: The inhibition of ROS accumulation by different antioxidants is specific to the site of
ROS generation as well as the antioxidant. This information should be useful for devising new
interventions to delay aging or treat ROS-related diseases.
Background
The production of reactive oxygen species (ROS) is greatly
increased under many conditions of toxic stress [1,2].
However, existing antioxidants appear to be relatively
ineffective in combating these problems, either because
they cannot reach the site of ROS production, which is fre-
quently within mitochondria, or because of their poor
ability to scavenge the damaging ROS. Identifying com-
pounds that directly block mitochondrial ROS produc-
tion may be a novel way to inhibit oxidative stress, and
perhaps delay aging and treat mitochondrial ROS-related
diseases. However, it remains a challenge to define both
the normal and pathologically relevant sites of ROS for-
mation in the mitochondrial electron transport chain
(ETC) and to find clinically useful agents that can mini-
mize mitochondrial ROS production.
The mitochondrial ETC is composed of a series of electron
carriers (flavoproteins, iron-sulfur proteins, ubiquinone
and cytochromes) that are arranged spatially according to
their redox potentials and organized into four complexes
(Figure 1). Electrons derived from metabolic reducing
equivalents (NADH and FADH2) are transferred into the
ETC through either complex I or complex II, and eventu-
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ally pass to molecular oxygen (O2) to form H2O in com-
plex IV. Electron transport through the mitochondrial
ETC is coupled to the transport of protons from the mito-
chondrial matrix to the mitochondrial intermembrane
space, generating an electrochemical proton potential that
is utilized by the ATP synthase (complex V) to form ATP
(Figure 1). Thermodynamically, all of these electron carri-
ers in their reduced state (standard redox potentials rang-
ing from - 0.320 to + 0.380 V) could pass their electrons
to O2 (standard redox potential: + 0.815 V) to form super-
oxide [3]. However, extensive studies with isolated mito-
chondria and submitochondrial particles detected only a
few ROS-forming sites in the mitochondrial ETC (Fig. 1B),
namely the ubiquinone site in complex III [4], the N2
iron-sulfur protein [5] or the ubiquinone-binding site [6]
in complex I, suggesting that most of the electron carriers
in the complexes may be shielded from O2. With isolated
mitochondria, the complex II substrate succinate supports
Oxidative Phosphorylation and the Mitochondrial Electron Transport Chain Figure 1
Oxidative Phosphorylation and the Mitochondrial Electron Transport Chain. A: Oxidative phosphorylation: the 
membrane topology of mitochondrial complexes, the sites of proton translocation and the targets of agents that affect the 
transmembrane proton gradient. B: The mitochondrial electron transport chain: the sites of ROS generation and the sites of 
action of commonly used respiratory inhibitors.Journal of Biomedical Science 2009, 16:98 http://www.jbiomedsci.com/content/16/1/98
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the highest ROS production rate in the absence of respira-
tory inhibitors. Most of the succinate-supported ROS pro-
duction is generated at the flavin mononucleotide (FMN)
group in complex I through reversed electron transfer [7-
9]. Reversed electron transfer occurs in the absence of ADP
when electrons derived from succinate flow in reverse to
complex I and reduce NAD+ to NADH. ROS production
through reversed electron transfer, which is more likely to
occur when the mitochondrial membrane potential is
high, is particularly sensitive to inhibition by agents such
as ADP and proton ionophore uncouplers which use or
dissipate the transmembrane proton gradient. However,
the relevance of the ROS-generating sites identified using
isolated mitochondria may be different from those pro-
ducing ROS in living cells is not entirely clear, in part
because mitochondria in living cells are simultaneously
exposed to a variety of substrates. In addition, many cellu-
lar factors that regulate mitochondrial electron transport
and ROS production are absent from isolated mitochon-
dria. Therefore, conclusions reached with in vitro data may
not accurately reflect mitochondrial ROS production in
living cells.
In the present report, we examined mitochondrial ROS
production in cultured cells under three pathophysiologi-
cally relevant situations where mitochondrially generated
oxidative stress is directly related to cell death: oxidative
glutamate toxicity, state IV respiration (respiration in the
absence of ADP) artificially induced with oligomycin, and
tumor necrosis factor α (TNFα)-induced cell death. We
also tested the effectiveness of various antioxidants on
ROS generation and cell death under these situations. It is
shown that the mitochondrial sites of ROS generation are
stressor-specific and that the accessibility of antioxidants
to ROS generated at each site within the ETC is distinct.
Based on these results and other evidence in the literature,
it is inferred that there are at least four ROS-generating
sites in the mitochondrial ETC in living cells: the FMN
group of complex I and the three ubiquinone-binding
sites in complexes I, II and III.
Methods
Materials and Cell Lines
Tissue culture reagents were purchased from Invitrogen
(San Diego, CA). 5-(and-6)-chloromethyl-2',7'-dichloro-
dihydrofluorescein diacetate (CM-H2DCFDA), 5,5',6,6'-
tetrachloro-1,1',3,3'-tetraethyl-benzimidazolcarbocya-
nine iodide (JC-1), 4,6'-diamidino-2-phenylindole
(DAPI), Hoechst H33342, and propidium iodide were
obtained from Molecular Probes (Eugene, OR). Iron
5,10,15,20-tetrakis-4-carboxyphenyl porphyrin (FeTCCP)
was from Frontier Scientific (Logan, UT). All other rea-
gents were from Sigma. All drugs were tested at 2-fold
serial dilutions higher and lower than that used in the
cited publications, and the minimum effective dose was
used.
HT-22 cells were derived from the immortalized mouse
hippocampal cell line HT-4 [10] and were cultured with
DMEM plus 10% fetal bovine serum (FBS). L929 murine
fibrosarcoma cells were obtained from the American Type
Culture Collection (ATCC, Rockville, MD) and grown in
DMEM with 10% FBS. Pancreatin (Invitrogen) was used
to dissociate cells from culture dishes.
Staining Cells with Fluorescent Dyes and Photomicroscopy
To study cellular superoxide level, cells were stained with
5 μM MitoSOX red for 10 min at 37°C and washed three
times before imaging. To assess mitochondrial membrane
potential, the cells were incubated with 2 μM JC-1 for 30
min at 37°C, and washed three times before imaging.
Nuclei were revealed by staining with the cell permeable
dye (Hoechst 33342) (10 μM) for 10 min at 37°C. Images
were taken with a Leica inverted microscope equipped
with a cooled Hamamatsu digital CCD camera (C4742-
95) and Openlab imaging software.
To study whether oxidized MitoSOX red by superoxide
accumulates in mitochondria, MitoSOX red (5 μM) was
oxidized in the absence of cells using superoxide gener-
ated from the xanthine/xanthine oxidase system at 37°C
for 100 min (100 μM xanthine, 50 mU/ml xanthine oxi-
dase, 2300 U/ml catalase). The reaction was stopped by
adding 100 μM allopurinol. HT-22 cells were then incu-
bated in oxidized probe solution for 10 min at 37°C. As a
control, a MitoSOX red sample went through the same
procedure as above but with the omission of xanthine
oxides to prevent the formation of superoxide. Further,
extensive information about the superoxide specificity of
MitoSOX red can be obtained from the manufacture,
Molecular Probes of Invitrogen.
Cellular ROS Levels
The cellular levels of ROS were determined using CM-
H2DCFDA and MitoSOX red. A protocol that measures
both superoxide and other ROS with CM-H2DCFDA and
MitoSOX red was developed. The cells were washed once
with DMEM and then dissociated from tissue culture
dishes with pancretin (Invitrogen, San Diego, CA) in
DMEM in the presence of 5 μM CM-H2DCFDA and 4 μM
MitoSOX red for 10 min at 37°C. After centrifugation, the
cell pellets were resuspended and washed once at room
temperature phenol red-free, HEPES-buffered DMEM
supplemented with 2% dialyzed FBS. The cells were then
resuspended in 750 μl of the same buffer containing 1 μg/
ml DAPI and kept on ice until flow cytometric analysis.
DAPI was used to gate for live cells. Flow cytometric anal-
ysis was performed with a Becton-Dickinson LSR three-
laser six-color analytic flow cytometer and the data acqui-Journal of Biomedical Science 2009, 16:98 http://www.jbiomedsci.com/content/16/1/98
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sition program CELLQuest™ (Becton-Dickinson, San Jose,
CA). Data were collected for 10,000 viable cells after gat-
ing out the dead cells using light scattering characteristics
and DAPI fluorescence. Median fluorescence intensities
(MFI) of the samples were determined. The excitation and
emission wavelength used for the dyes are λex/λem = 345/
455 nm for DAPI, λex/λem = 475/525 nm for dichlorofluo-
rescein (DCF), and λex/λem = 510/580 nm for MitoSOX
red. Color compensation was applied to properly analyze
the multicolor data. With the LSR three-laser six-color
analytic flow cytometer, the optical layout of this machine
dictates that cells pass through and are analyzed first by
the 488 nm excitation beam before they encounter the UV
beam. Cells typically encounter the UV beam approxi-
mately 17 microseconds after they have been analyzed by
the 488 nm beam for 10 microseconds, therefore it is
physically impossible for the UV beam to affect DCF or
MitoSOX fluorescence measured with the 488 nm beam.
Photobleaching is therefore minimal and is not a recog-
nized problem in analytical flow cytometers such as the
LSR. In all cases controls were done to insure that any
added reagents, such as antioxidants, do not directly con-
tribute to the fluorescent signals.
Determination of Mitochondrial Membrane Potential By 
Flow Cytometry
JC-1 was used to determine the mitochondrial membrane
potential [11]. Cells were washed once with fresh culture
medium to remove test compounds before incubating in
2 μM JC-1 for 30 min at 37°C. The cells were then disso-
ciated with pancretin and washed once in room tempera-
ture phenol red-free, HEPES-buffered DMEM
supplemented with 2% dialyzed FBS. Cell pellets were
then resuspended in the same buffer with 1 μg/ml DAPI
for the gating of dead cells. Flow cytometric analysis was
performed on 10,000 viable cells with a LSR three-laser
six-color analytic flow cytometer and CELLQuest™ soft-
ware (Becton-Dickinson, San Jose, CA). The excitation
and emission wavelength used for the dyes are λex/λem =
345/455 nm for DAPI, λex/λem = 488 nm/530 nm for the
JC-1 monomer and 590 nm for the JC-1 aggregate.
Cell Viability Assay
For oligomycin- and TNFα-induced cytotoxicity of HT-22
or L929 cells, cell viability was determined by trypan blue
(0.4%) exclusion after overnight treatment. About 500
cells were counted for each sample. The LDH release assay
was used in some cases according to manufacturer's
(Sigma) instructions.
Statistics
Statistical analysis was performed with GraphPad Prism
software (San Diego, CA). Most of the data are presented
as mean ± standard error of the mean (SEM) of three inde-
pendent determinations. In some cases ANOVA analysis
was used to evaluate the data followed by a Tukey post-
hoc test.
Results
In order to identify sites of ROS production under condi-
tions of stress, it is first necessary to understand ROS pro-
duction in normal cells and to verify that the reagents
used to study mitochondrial ROS production function in
cells as they do with isolated mitochondria. Since respira-
tory inhibitors have been used extensively to study ROS
production by isolated mitochondria, we used these rea-
gents to identify sites of cellular ROS production in the
mouse hippocampal nerve cell line HT-22. Cellular ROS
were assayed using both 5-(and-6)-chloromethyl-2', 7'-
dichlorodihydrofluorescein diacetate (CM-H2DCFDA)
and MitoSOX red. CM-H2DCFDA has been used exten-
sively to measure cellular H2O2 and other ROS, but it does
not measure superoxide directly [12]. MitoSOX red is a
selective indicator of mitochondrial superoxide that is
better than the commonly used superoxide probe dihy-
droethidium in terms of both mitochondrial localization
and specificity toward superoxide [13]. MitoSOX red is
selectively targeted to mitochondria and is able to com-
pete efficiently with superoxide dismutase (SOD) for
superoxide. Oxidized MitoSOX red becomes highly fluo-
rescent upon binding nucleic acids, and MitoSOX red pre-
oxidized by superoxide does not accumulate in
mitochondria [13]. These characteristics make MitoSOX
red a selective indicator of mitochondrial superoxide pro-
duction. As shown in Figure 2, cellular MitoSOX red stain-
ing is limited to mitochondria and 5 to 8 nuclear spots.
The fluorescence intensity in both mitochondria and the
nuclear spots is greatly increased by the ATP synthase
inhibitor oligomycin and the complex III/I inhibitor
myxothiazol (Figure 2B and 2D). Iron 5,10,15,20-tetrakis-
4-carboxyphenyl porphyrin (FeTCPP), a small molecule
SOD mimetic [14], almost completely abolished the oli-
gomycin-induced fluorescence signal, indicating that the
fluorescence was indeed caused by superoxide (Figure
2C). The nuclear MitoSOX red fluorescent spots might
represent superoxide produced by cytoplasmic/nuclear
ROS generator(s) or by superoxide released from mito-
chondria. The latter possibility is supported by the obser-
vation that following oligomycin and myxothiazol
treatment, there is an increased intensity of the nuclear
spots (Figure 2B and 2D). In confirmation of the findings
by Robinson et al. [13]. MitoSOX red pre-oxidized by
superoxide from the xanthine/xanthine oxidase system
did not accumulate in mitochondria, but showed a diffuse
cytoplasmic staining and bright nuclear spots (Figure 2E).
In contrast, MitoSOX red that went through the same xan-
thine/xanthine oxidase treatment except with xanthine
oxidase omitted to prevent the formation of superoxide,
showed the characteristic mitochondrial staining pattern
(Figure 2F). These results confirm that MitoSOX red isJournal of Biomedical Science 2009, 16:98 http://www.jbiomedsci.com/content/16/1/98
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selectively taken up by mitochondria and that its fluores-
cence signal represents mostly mitochondrially-generated
superoxide.
Simultaneous flow cytometric analysis of DCF-detectable
ROS and MitoSOX-detectable superoxide revealed a basal
level of both cellular superoxide and H2O2 and other ROS
production in HT-22 cells (Figure 3A). Treatment of the
cells with various respiratory inhibitors demonstrated the
complex nature of ROS production in living cells (Table
1). Consistent with the in vitro finding that inhibitors of
the quinone-binding site in complex I induce ROS pro-
duction [6,8], the complex I inhibitors rotenone and pier-
cidin A increased cellular ROS levels by 30 to 120%.
Interestingly, amytal, another inhibitor of the quinone-
binding site in complex I slightly decreased cellular ROS
levels. This may reflect the complex nature of the qui-
none-binding sites in complex I and the route of electron
transfer through these sites, which is not yet completely
understood [15]. The complex III inhibitors (antimycin A,
Assessing Cellular Levels of Superoxide with the Superoxide Indicator MitoSOX Red. HT-22 cells were stained with 5 μM  MitoSOX red for 10 min at 37°C before imaging Figure 2
Assessing Cellular Levels of Superoxide with the Superoxide Indicator MitoSOX Red. HT-22 cells were stained 
with 5 μM MitoSOX red for 10 min at 37°C before imaging. A: Control. B: The cells were treated with 10 μg/ml oligo-
mycin for 2 hr. C: The cells were treated with 10 μg/ml oligomycin and 50 μM FeTCPP for 2 hr. D: The cells were treated with 
1 μM myxothiazol for 2 hr. E: The cells were treated with 10 μg/ml oligomycin for 2 hr and stained with MitoSOX red that had 
been oxidized by superoxide from the xanthine/xanthine oxidase system. F: The cells were treated with 10 μg/ml oligomycin 
for 2 hr and stained with MitoSOX red that went through the same xanthine/xanthine oxidase procedure as in E except that 
xanthine oxidase was omitted to prevent the formation of superoxide.Journal of Biomedical Science 2009, 16:98 http://www.jbiomedsci.com/content/16/1/98
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myxothiazol and stigmatellin) all increased cellular ROS
levels while the inhibition of complex IV with NaN3 had
no significant effect. These results are consistent with data
obtained from isolated mitochondria [6]. The complex II
inhibitor theonyltrifluoroacetone (TTFA) increased cellu-
lar ROS levels by 30 to 50% and the ATP synthase inhibi-
tor oligomycin increased the cellular ROS levels over 10-
fold (Table 1 and Fig. 3A). The proton ionophore carbo-
nyl cynide p-trifluoromethoxyphenylhydrozone (FCCP)
and the flavin protein inhibitor diphenyleneiodonium
(DPI), both of which inhibit ROS production by isolated
mitochondria through reversed electron transfer [12],
increased the total cellular ROS levels by 60 to 120%, sug-
gesting that ROS production through reversed electron
transfer does not contribute significantly to the basal cel-
lular level in this cellular model. The effect of FCCP and
DPI on basal cellular ROS level may be indirect and
related to their disturbance of cellular metabolism. The
mechanism of this effect is unknown.
Finally, some inhibitors such as myxothiazol and oligo-
mycin induce differential levels of DCF-detectable ROS
and MitoSOX red-detected superoxide. For example,
myxothiazol induced a 72% increase in DCF-detectable
ROS and a 423% increase in superoxide while oligomycin
induced an 800% increase in DCF-detectable ROS and
only a 260% increase in superoxide (Table 1). Since
MitoSOX red competes efficiently with SOD, these differ-
ences may be explained by the relative availability of SOD
around the ROS-generating sites affected by these respira-
tory inhibitors.
The data in Figure 2 and Table 1 confirm that mitochon-
dria can be a major cellular ROS generator in living cells
and show that the effects of most respiratory inhibitors on
cellular ROS level are consistent with their mitochondrial
action as previously revealed with isolated mitochondria.
However, the relevance of mitochondrial ROS production
induced by respiratory inhibitors to mitochondrial ROS
production under various pathophysiological conditions
is still not clear. This question was addressed in the fol-
lowing sections.
Oligomycin-Induced Mitochondrial Oxidative Stress
Studies with isolated mitochondria show that ROS pro-
duction is the greatest during state IV respiration (respira-
tion in the absence of ADP). State IV respiration reflects
conditions where there is an excess of ATP and a defi-
ciency of ADP [9]. The ATP synthase inhibitor oligomycin
is often used to fix mitochondria in state IV respiration
because the transmembrane proton gradient can no
longer be used to convert ADP into ATP, resulting in a
highly increased membrane potential. In a pathological
condition similar to oligomycin treatment, the T8993G
mutation in the mitochondrial ATPase-6 gene inhibits
ATP synthase activity and causes high mitochondrial
membrane potential, ROS over-production and neuro-
genic ataxia retinitis pigmentosa [16].
Oligomycin induced the highest cellular ROS levels (over
10-fold) of all the respiration inhibitors tested (Table 1)
and is also cytotoxic (Figure 3B). As expected, oligomycin
increases the mitochondrial membrane potential as indi-
cated by JC-1 staining (Figure 3C). The site of oligomycin-
induced ROS generation was investigated using addi-
tional respiratory inhibitors. As shown in Table 2, the only
respiratory inhibitor that significantly reduced oligomy-
cin-induced ROS production is the complex II inhibitor
theonyltrifluoroacetone (TTFA), which interferes with the
quinone-binding site of complex II. TTFA also partially
protects the cells from oligomycin-induced cell death
(Table 2). This result suggests that about 20% of the ROS
induced by oligomycin comes from the ubiquinone-bind-
ing site of complex II. The proton ionophore uncoupler
Table 1: Effects of Respiratory Inhibitors on ROS Levels in HT-22 Cells
Respiratory inhibitors Site of action ROS level (% of control)
DCF MitoSOX
Amytal, 100 μM Complex I 83 ± 10* 92 ± 3
Rotenone, 2 μM Complex I 129 ± 7* 167 ± 27*
Piercidin A, 1 μM Complex I 213 ± 40* 221 ± 35*
TTFA, 100 μM Complex II 146 ± 20* 133 ± 14*
Antimycin A, 2 μM Complex III 125 ± 10* 123 ± 6*
Stigmatellin, 1 μM Complex III 111 ± 5 124 ± 6*
Myxothiazol, 1 μM Complex III and I 172 ± 30* 523 ± 50*
NaN3, 5 mM Complex IV 99 ± 5 95 ± 5
Oligomycin, 10 μg/ml ATP synthase 904 ± 180* 360 ± 30*
FCCP, 5 μMH + ionophore 137 ± 6* 123 ± 6*
DPI, 1 μM Flavin protein 150 ± 14* 171 ± 18*
HT-22 cells were treated with the respiratory inhibitors at the indicated concentrations for 2 hr at 37°C. Cellular ROS levels were determined 
with CM-H2DCFDA and MitoSOX red as described in the methods section. DCF: dichlorofluorescein. *: Significantly different from control by 
ANOVA (P < 0.05).Journal of Biomedical Science 2009, 16:98 http://www.jbiomedsci.com/content/16/1/98
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FCCP and the flavin protein inhibitor DPI do not have a
significant effect on oligomycin-induced ROS production
and cell death, suggesting that ROS production at the
FMN group of complex I through reversed electron trans-
fer does not contribute significantly to oligomycin-
induced ROS production and cytotoxicity. It is not clear at
present where the rest of the oligomycin-induced ROS is
produced, but, as described in the Discussion, it is likely
from the quinone-binding sites in complex I and/or com-
plex III.
Oligomycin-induced cell death is blocked by the hydro-
phobic antioxidant vitamin E. However, a variety of rela-
tively hydrophilic antioxidants including vitamin C, some
flavonoids (e.g. kaempferol, luteolin, quercetin and bai-
calein), N-acetylcysteine, butylated hydroxyanisole
(BHA), butylated hydroxytoluene (BHT) and nordihydro-
guaiaretic acid did not block oligomycin-induced cell
death at concentrations between 10 and 100 μM (Table 2
and Table 3), suggesting that most of the cytotoxic ROS is
released into the hydrophobic domain of the mitochon-
drial membrane that is not accessible to hydrophilic anti-
oxidants. Indeed, as shown in Table 2, vitamin E markedly
inhibited oligomycin-induced ROS production while the
hydrophilic vitamin E analog 2,2,5,7,8-pentamethyl-6-
chromanol had no significant effect. The superoxide scav-
enger FeTCPP at 50 μM almost completely blocked oligo-
mycin cytotoxicity (Table 3), suggesting that superoxide
Oligomycin-induced Cellular ROS Production and Cell Death in HT-22 Cells Figure 3
Oligomycin-induced Cellular ROS Production and Cell Death in HT-22 Cells. A: Flow cytometric analysis of cellular 
ROS levels with the simultaneous use of CM-H2DCFDA and MitoSOX red and the effect of oligomycin treatment (10 μg/ml, 2 
hr). DCF: dichlorofluorescein. MFI: median fluorescence intensity. B: Phase contrast images. Images were taken after the cells 
were treated or untreated with 10 μg/ml oligomycin for 8 hr. C: JC-1 staining. The cells were treated or untreated with 10 μg/
ml oligomycin for 2 hr.Journal of Biomedical Science 2009, 16:98 http://www.jbiomedsci.com/content/16/1/98
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may be the damaging ROS. Vitamin E is not known to be
an efficient superoxide scavenger. It is therefore possible
that the inhibition of oligomycin-induced superoxide by
vitamin E may be more related to an ability to inhibit
superoxide production than its ability to scavenge super-
oxide.
Oxidative Glutamate Toxicity Induces Dramatic ROS 
Production From the FMN Group of Complex I
A reduction in the level of intracellular glutathione (GSH)
is associated with neurodegenerative diseases such as Par-
kinson's disease [17]. A robust model of mitochondrial
ROS-induced cell death caused by GSH depletion is oxida-
tive glutamate toxicity. Oxidative glutamate toxicity has
been extensively studied using the mouse hippocampal
cell line HT-22 and immature primary cortical neurons
[18,19]. In this model, extracellularly added glutamate
inhibits cystine uptake through the cystine/glutamate ant-
iporter, resulting in the depletion of intracellular cysteine
and GSH. When the cellular GSH level drops below 20%
of the control, an explosive generation of ROS occurs that
is required for the subsequent cell death. The source of
this robust ROS generation is from mitochondria because
both the ROS production and the subsequent cell death
are blocked by the proton ionophore FCCP that dissipates
the mitochondrial transmembrane proton gradient [19].
These findings suggest that ROS production in oxidative
glutamate toxicity might proceed through reversed elec-
Table 2: Effects of Respiratory Inhibitors and Antioxidants on Oligomycin-Induced Cell Death and ROS Production
Treatments Cell Viability (% of Control) Percent of Oligomycin-Induced ROS Level
Trypan LDH DCF MitoSOX
Oligomycin (O), 10 μg/ml 0 0 100 100
O + Amytal, 100 μM 0 0 97 ± 3 93 ± 4
O + Rotenone, 2 μM 0 0 90 ± 5 97 ± 3
O + TTFA, 100 μM 41 ± 9* 52 ± 9* 84 ± 6* 79 ± 6*
O + Antimycin A, 2 μM 0 0 92 ± 5 114 ± 10
O + Stigmatellin, 1 μM0 0 9 6  ±  5 1 0 7  ±  8
O + FCCP, 5 μM0 0 9 0  ±  6 1 0 6  ±  6
O + DPI, 1 μM 0 0 97 ± 5 132 ± 8*
O + Vitamin E, 100 μM 93 ± 4* 100* 60 ± 5* 59 ± 6*
O + 2,2,5,7,8-Pentamethyl- 0 0 98 ± 5 97 ± 3
6-chromanol, 100 μM
O + Vitamin C, 100 μM 0 0 85 ± 7 91 ± 7
Cellular ROS levels were determined in HT-22 cells with CM-H2DCFDA and MitoSOX red after 2 hr of treatment (Figure 3A) and inhibitors were 
added at the same time as oligomycin. Cell viability was determined after overnight treatment either by the trypan blue assay or LDH release assay. 
*: Significantly different from control by ANOVA (P < 0.05).
Table 3: The Effects of Commonly Used Antioxidants or Inhibitors of ROS-Generating Enzymes on TNFα-, Glutamate- and 
Oligomycin-Induced Cytotoxicity.
Cell Viability (% of control)
Antioxidants or inhibitors TNFα Glutamate Oligomycin
No antioxidant or inhibitor 0 0 0
Vitamin E, 100 μM 0 100* 93 ± 4*
Vitamin C, 100 μM0 1 0 0 * 0
BHA, 100 μM 95 ± 3* 92 ± 4* 0
BHT, 100 μM 0 45 ± 6* 0
Idebenone, 10 μM 0 97 ± 3* 0
N-Acetylcysteine, 100 μM0 1 0 0 * 0
Quercetin, 10 μM 0 96 ± 4* 0
L-NAMEa, 100 μM0 0 0
Allopurinol, 100 μM0 0 1 2  ±  3 *
Desferoxamine, 100 μM 0 91 ± 4* 0
FeTCPP, 50 μM0 0 9 5  ±  4 *
TNFα cytotoxicity was assayed with L929 cells as described in the legend of Figure 3. Oxidative glutamate toxicity (5 mM) and oligomycin (10 μg/
ml)-induced cytotoxicity were determined with HT-22 cells after overnight treatment. aL-NAME: NG-monomethyl-L-arginine methyl ester.
*: Significantly different from "No antioxidant or inhibitor" by ANOVA (P < 0.05).Journal of Biomedical Science 2009, 16:98 http://www.jbiomedsci.com/content/16/1/98
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tron transfer at the FMN group of complex I as with iso-
lated mitochondria [8]. If this is the case, then the
mitochondrial membrane potential should be increased
following glutamate treatment and the flavin protein
inhibitor DPI should be able to inhibit both ROS produc-
tion and the subsequent cell death (Figure. 1).
As shown in Figure 4, the addition of glutamate to HT-22
cells results in hyperpolarization of the mitochondria
membrane (Figure 4A) and an over 20-fold increase in
total cellular ROS levels as measured by the fluorescent
ROS probes CM-H2DCFDA and MitoSOX red (Figure 4B).
The flavin protein inhibitor DPI not only prevents gluta-
mate-induced ROS production but also the subsequent
cell death (Figure 4B and 4C). Despite the fact that com-
plex II also contains a flavin group, low concentrations of
DPI selectively inhibit the activity of complex I in isolated
mitochondria [8] in intact cells [20] and in animals [21].
It is possible that DPI at the concentration used (50 nM)
also inhibited other ROS-generating flavin oxidases such
as nitric oxide synthase, xanthine oxidase and monoam-
ine oxidase. However, specific inhibitors of these flavin
Oxidative Glutamate (Glu) Toxicity Increases Mitochondrial Membrane Potential and Cellular ROS Levels: Inhibition by Diphe- nyleneiodonium (DPI) Figure 4
Oxidative Glutamate (Glu) Toxicity Increases Mitochondrial Membrane Potential and Cellular ROS Levels: 
Inhibition by Diphenyleneiodonium (DPI). A: HT-22 cells were treated as indicated, followed by JC-1 staining to reveal 
the mitochondrial membrane potential. B: HT-22 cells were treated for 8 hr with 5 mM glutamate or 5 mM glutamate plus 50 
nM DPI. Cellular ROS levels were then measured with flow cytometry using CM-H2DCFDA and MitoSOX red. *: Significantly 
different from glutamate-treated cells by paired Student's t-test (p < 0.05). C: Phase contrast images of HT-22 cells treated with 
glutamate or glutamate plus DPI.Journal of Biomedical Science 2009, 16:98 http://www.jbiomedsci.com/content/16/1/98
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oxidases at effective concentrations do not inhibit the
ROS production and the cell death in oxidative glutamate
toxicity (Table 3 and data not shown) [also see [19]].
Because the proton ionophore FCCP blocks ROS produc-
tion and cell death in oxidative glutamate toxicity [19]
and FCCP is also known to block the ROS production by
isolated mitochondria through reversed electron transfer
at the FMN group of complex I [8] it follows from the
results in Figure 4 that the FMN group of complex I is the
major source of ROS production in oxidative glutamate
toxicity.
TNFα Induces ROS Production From the Quinone-Binding 
Sites of Complexes I and II
TNFα is a major inflammatory cytokine that induces,
among many other activities, the death of sensitive nerve
cells [see, for example, McCoy, 2006] [22]. TNFα causes
necrotic cell death in mouse L929 fibrosarcoma cells
through an increase in mitochondrial ROS generation as
detected by the ROS probe dihydrorhodamine 123 and a
variety of other methods [23]. The L929 cells are used here
instead of nerve because of the extensive literature on
TNFα toxicity with these cells. It has been suggested that
TNFα-induced mitochondrial ROS is produced from the
ubiquinone-binding sites of both complex I and complex
II because the complex I inhibitor amytal and the complex
II inhibitor TTFA block TNFα-induced cell death and
because both amytal and TTFA are known to act at the ubi-
quinone-binding sites [23]. We used the TNFα/L929 cell
system (Figure 5A and 5B) to further investigate the sites
of TNFα-induced mitochondrial ROS generation by the
simultaneous detection of cellular DCF-detectable ROS
and MitoSOX-detectable superoxide. As shown in Figure
5D and 5E, TNFα treatment induced a time dependent
increase in both mitochondrial membrane potential as
defined by JC-1 fluorescence and an ~100% increase in
cellular ROS levels after 3 hr of treatment. The complex I
inhibitor amytal and the complex II inhibitor TTFA
reduced both TNFα-induced ROS increase and cell death,
and the combination of amytal and TTFA completely
blocked TNFα-induced ROS and cell death (Figure 5C,
and 5F). Other respiratory inhibitors tested, including
Effects of TNFα on Mitochondrial Membrane Potential, Cellular ROS Levels and Cell Viability in L929 Cells Figure 5
Effects of TNFα on Mitochondrial Membrane Potential, Cellular ROS Levels and Cell Viability in L929 Cells. A: 
Control. B: The cells were treated with 10 ng/ml TNFα and 1 μg/ml actinomycin D for 16 hr. C: The cells were treated with 10 
ng/ml TNFα and 1 μg/ml actinomycin D plus 100 μM amytal for 16 hr. D: The cells were treated with 10 ng/ml TNFα and 1 μg/
ml actinomycin D for the indicated periods of time. E: The cells were treated with 10 ng/ml TNFα and 1 μg/ml actinomycin D 
alone or plus 100 μM of the indicated agents for 3 hr. F: The cells were treated with 10 ng/ml TNFα and 1 μg/ml actinomycin 
D alone or plus 100 μM of the indicated agents for 16 hr. *: Significantly different from TNFα-treated cells by paired Student's 
t-test (p < 0.05).Journal of Biomedical Science 2009, 16:98 http://www.jbiomedsci.com/content/16/1/98
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rotenone, piercidin A, antimycin A, stigmatellin, myxothi-
azol, NaN3, FCCP and DPI, had no significant effects on
TNFα-induced ROS increase or cell death. These results
are consistent with the suggestion that TNFα induces
mitochondrial ROS production from the ubiquinone-
binding sites of both complex I and complex II [22].
TNFα-induced cell death in L929 cells is blocked by the
antioxidant BHA (Table 3), but is not inhibited by a vari-
ety of both hydrophobic and hydrophilic antioxidants
including vitamin E, vitamin C, flavonoids (kaempferol,
luteolin, quercetin and baicalein), N-acetylcysteine, BHT
and nordihydroguaiaretic acid. Therefore, TNFα-induced
ROS is released into a domain that is not accessible to
these antioxidants.
Discussion
The work presented above analyzes mitochondrial ROS
generation in cells under both normal conditions and
under three situations reflecting nerve cell death where
mitochondrially generated oxidative stress is directly
involved: TNFα-induced cell death, oxidative glutamate
toxicity and oligomycin-induced state IV respiration.
These experiments revealed the complex nature of mito-
chondrial ROS production in cells. The three different
stress-induced situations described in this study all
resulted in an increase of mitochondrial membrane
potential, yet the sites of ROS production and the
amounts of ROS produced are all very different. Based on
in vitro studies with isolated mitochondria and respira-
tory inhibitors, it has been estimated that between 0.15%
to 4% of the oxygen consumed by mitochondria is con-
verted to superoxide [24]. However, the amount of oxy-
gen that is converted to superoxide by mitochondria in
vivo is determined by both the respiratory state and extrin-
sic factors. A variety of factors and conditions are known
to modulate mitochondrial ROS production, including
inflammatory cytokines such as TNF-α and IL-1 [25]
mitochondrial thiol status [26], oncogenes [27], lipid
mediators such as 15-deoxy-Δ12,14-prostaglandin J2 [28],
excitotoxicity [29] and toxic chemicals such as dioxin
[30]. It is therefore important to understand how these
various stresses modulate mitochondrial ROS production
using living cells and in vivo model systems.
The major difficulty in studying mitochondrial ROS pro-
duction in intact cells has been in being certain that cellu-
lar ROS detected with a fluorescence probe is from
mitochondria and not from other ROS generators. This is
because there have been no selective indicators for mito-
chondrial ROS in intact cells and because some of the
commonly used respiratory inhibitors may have targets
other than mitochondria in intact cells. However, the
newly developed MitoSOX red used in this study is a good
selective indicator of mitochondrial superoxide [13], and
the non-mitochondrial actions of the respiratory inhibi-
tors could be examined to determine if their effects are
consistent with their intended targets.
TTFA is commonly assumed to act upon the quinone-
binding sites of complex II, but it also inhibits malate
dehydrogenase [31] and liver/plasma carboxylesterase
[32] at the concentrations used here (50 to 100 μM). Inhi-
bition of carboxylesterase could limit the availability of
DCF to react with ROS and lead to lowered estimate of
DCF-detectable ROS. However, in our study, cellular ROS
is measured with both CM-H2DCFDA and MitoSOX red,
and MitoSOX red is not an ester and therefore not sensi-
tive to carboxylesterase inhibition. Since no differential
effects of TTFA on DCF and MitoSOX red signals are
detected (Table 1 and 2, Figure 5), the effect of TTFA on
carboxylesterase does not appear to be a concern with the
cellular models used here. Other inhibitors of malate
dehydrogenase (thyroxine and chlorothricin) also failed
to mimic the effects of TTFA on oligomycin- and TNFα-
induced ROS production and cell death (data not shown).
These results suggest that the effect of TTFA on cellular
ROS production is consistent with its action on the qui-
none-binding sites of complex II. Similarly, the effect of
the flavin protein inhibitor DPI on oxidative glutamate
toxicity is most consistent with its selective interaction
with the FMN group of complex I.
The oxidative glutamate toxicity data show that the FMN
group in complex I can be a robust ROS-generating site in
living cells under conditions that favor reversed electron
transfer such as low intracellular cysteine/GSH. The stud-
ies on oligomycin- and TNFα-induced ROS production
indicate that the ubiquinone-binding sites in both com-
plex I and complex II can also serve as ROS-generating
sites in intact cells [23]. Although lacking a pathophysio-
logical example, it is likely that the ubiquinone-binding
site(s) in complex III is also a ROS-generating site in living
cells. Therefore, there are at least three and possibly four
ROS-generating sites in the mitochondrial ETC that can
produce ROS in cells, namely, the FMN group of complex
I and the three ubiquinone-binding sites in complexes I,
II and III (Figure 1). However, there are at least two qui-
none-binding sites within each complex and the route of
electron transfer through these sites is not completely
understood [15]. The details of ROS generation around
these quinone-binding sites as well as their modulation
remain to be established.
Although most of the electron carriers in the mitochon-
drial ETC have the potential to pass electrons to O2 to
form superoxide, the fact that only a few actually generate
superoxide suggests that most are shielded from O2.
Because both FMN and ubiquinone have access to O2 and
both can form a stable semiquinone free radical state that
can pass electrons to O2, it is probably not a coincidenceJournal of Biomedical Science 2009, 16:98 http://www.jbiomedsci.com/content/16/1/98
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that they have been associated with ROS production.
However, whether ubisemiquinone itself or the iron-sul-
fur center at the quinone-binding site is the source of
superoxide is still not resolved [5].
Our data suggest that the accessibility of the four mito-
chondrial ETC ROS-generating sites to commonly used
antioxidants as well as an antioxidant's ability to block
toxicity is more specific than commonly assumed. While
ROS produced around the FMN group in complex I can be
scavenged by a variety of both hydrophilic and hydropho-
bic antioxidants that also block cell death in oxidative
glutamate toxicity (Table 3) (see also [19]), ROS gener-
ated around the quinone-binding sites in complexes I and
II, as is seen following TNFα and oligomycin treatment,
are not accessible to most of the commonly used antioxi-
dants shown in Table 3. Therefore specific antioxidants
with accessibility to ROS generated at the quinone-bind-
ing sites or specific inhibitors of ROS production at these
sites are needed to reduce ROS production in these patho-
physiological situations.
ROS production around the quinone-binding sites in
complex I has long been recognized with studies using
isolated mitochondria [5] and is believed to be important
in the pathogenesis of Parkinson's disease and a number
of other diseases associated with complex I deficiency
[33]. Most complex I inhibitors acting around the qui-
none-binding sites of complex I (such as rotenone and
piercidin A) increase ROS production by themselves
(Table 1). However, the clinically useful amytal is an
interesting exception. It both decreased cellular ROS level
in unstressed cells (Table 1) and inhibited ROS produc-
tion by TNFα (Figure 5E). These results suggest that it may
be possible to find additional, more potent compounds
that inhibit ROS production at the quinone-binding sites
of complex I.
Studies with isolated mitochondria have not yet identified
complex II as a ROS-generating site, but medical evidence
suggests that complex II can be an important source of
pathological ROS production. Genetic defects in human
complex II result in a number of diseases that often man-
ifest as tumors and neurological disorders associated with
the production of ROS (for review, see [34]). Ishii et al.
[35] also found that a mutation in the cytochrome b of
complex II causes oxidative stress and rapid aging in nem-
atodes. More importantly, mitochondrial ROS overpro-
duction resulting from diabetic hyperglycemia is largely
blocked by the complex II inhibitor TTFA [36]. Therefore,
ROS production by complex II is not only important in
rare mitochondrial diseases but also important in a major
disease such as type II diabetes. In the present study, we
found that TTFA inhibited the cellular ROS production
induced by both oligomycin and TNFα, further support-
ing the idea that complex II can be an important source of
ROS in cells. Sun et al. [37] have recently reported the first
crystal structure of mammalian complex II and demon-
strated two quinone-binding sites through complex II-
TTFA complex. This information should be very useful for
understanding ROS production by complex II and for
designing inhibitors of complex II ROS production.
A variety of other diseases are also associated with mito-
chondrial respiratory chain deficiencies [2]. Using ele-
vated expression of mitochondrial manganese SOD as a
marker of increased superoxide production, skin fibrob-
lasts or muscle biopsies from patients with mitochondrial
respiratory chain deficiencies in complexes I, II or V were
found to have increased superoxide production [16]. Sur-
prisingly, a literature search failed to find reports about
superoxide overproduction caused by complex III muta-
tions even though complex III is often suggested to be the
largest source of mitochondrial ROS based on studies
using isolated mitochondria and the complex III inhibitor
antimycin A. In contrast, complex V deficiency caused by
the T8993G mutation in the mitochondrial ATPase-6 gene
induces ROS overproduction and neurogenic ataxia retin-
itis pigmentosa [16]. Oligomycin treatment mimics this
pathological condition. We have found that oligomycin-
induced ROS production and cell death is blocked by vita-
min E, suggesting that vitamin E treatment may be bene-
ficial to patients with complex V deficiency.
Conclusion
Our study has demonstrated the complex nature of mito-
chondrial ROS production in cells under several patho-
physiological conditions. It is inferred that there are at
least four ROS-generating sites in the mitochondrial ETC
that can produce ROS in cells: the FMN group of complex
I and the three ubiquinone-binding sites in complex I, II
and III. The accessibility of commonly used antioxidants
to these ROS-generating sites varies tremendously. Since
ROS production around the ubiquinone-binding sites
within complex I to III is associated with major diseases
and is not accessible to existing antioxidants, new drugs
that can inhibit ROS production from these sites may
prove to be the most useful in treating mitochondrial
ROS-related diseases such as Parkinson's disease and type
II diabetes.
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